Panobinostat’s Questionable Magnitude Of Benefit Can’t Outweigh Toxicities, Panel Says

Novartis shouldn’t give up on drug for relapsed multiple myeloma, FDA’s Oncologic Drugs Advisory Committee says, even as panel votes against approval based on progression-free survival data.